Skip to main content
An Official Vermont Government Website

January - March 2024

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/02.07.2024_Letter%20to%20Vermont%20Notifying%20%26%20Reporting%20New%20Drugs.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/03.12.2024_Letter%20to%20Vermont%20Notifying%20%26%20Reporting%20New%20Drugs.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/2024%20-%20AvKare%20-%20Launch%203.1.24%20-%20Pirfenidone%20801mg.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/2024%20-%20AvKare%20-%20Launch%203.6.24%20-%20Pirfenidone%20267mg.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/2024-3-11%20Vermont%203%20Day%20Letter%20Daraprim%20Signed.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/2024-3-11%20Vermont%2030%20Day%20Letter%20Daraprim%20Signed.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Acadia_VT_Submission_20240228-163515.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Acadia_VTS_Submission_20240229-153316.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Adalimumab-aacf%20VT%2030-day%20Report.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Apellis_2023_VT_Sample_Submission_8113f02_2-16-2024-1.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Aucta%20-%20Notice%20of%20New%20Drug%20Introduction%20Pursuant%20to%2018%20V.S.A%20%C2%A7%204637(c).pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/bluebird%20bio%20Lyfgenia%20VT%20New%20Drug%20Report.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Bluebird%20Bio%20Vermont%20Expenditure%20Disclosure%20Report%202023.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/CASGEVY%20Notification%20Pursuant%20to%2018%20V%20S%20A%20%20%C2%A7%204637(c).pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Celltrion%20USA_Zymfentra%20120mg_VT%203Day_03.15.24.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Celltrion_Yuflyma%2080MG_%20VT_30%20Day_01.26.24.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Drug%20Price%20Transparency%20-%203%20Day%20Notice%20-%20VT%20Carboprost%20PFS.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Drug%20Price%20Transparency%20-%2030%20Day%20Notice%20-%20VT%20Carboprost%20PFS.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Eisai_Catalyst%20Fycompa%20Transition%20Notification%20-%20State%20Price%20Reporting.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Eton%20VT%20New%20Drug%20Notice.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Fresenius%20Kabi-%20Cyclophosphamide%20VT%20New%20Drug%203-day%20Notice.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Fresenius%20Kabi-%20Cyclophosphamide%20VT%20New%20Drug%2030-day%20Report.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Kyowa%20Kirin%2C%20Inc.%202023%20Vermont%20Prescribed%20Products%20Expenditure%20and%20Sample%20Disclosure%20Report%20Cover%20Letter.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Lyfgenia%20VT%203-day.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Meitheal%20Pharmaceuticals%2C%20Inc.%20New%20Drug%20Report%20-%20Thiotepa%20for%20Injection%20USP%20100mg.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/New%20Drug%20Launch%20Notification%20-%20RINVOQ%20LQ.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/New%20Drug%20Notice%20%20-%20Filsuvez%20(10122).pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/New%20Drug%20Notice%20for%20INA%20Vermont%20-%20Amcinonide%20Cream.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/New%20Drug%20Notice%20for%20Quallent%20New%20Hampshire%20-%20Adalimumab.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/New%20Product%20Launch%20Notification%20-%20VT%20-%20Geron%20Corp.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/NNI%20VT%2018%20V.S.A.%204637(b)%203-Day%20Notice%20RIVFLOZA%2022Feb2024.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/NNI%20VT%2018%20V.S.A.%204637(b)%2030-Day%20Notice%20RIVFLOZA_21Mar2024_Signed.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Notice%20of%20a%20New%20Prescription%20Drug%20Pursuant%20to%2018%20V.S.A%20%C2%A7%204637(b)%20-%20BOSULIF.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Notice%20of%20a%20New%20Prescription%20Drug%20Pursuant%20to%2018%20V.S.A%20%C2%A7%204637(c)%20-%20BOSULIF.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Notice%20of%20New%20Drug%20Introduction%20Pursuant%20to%2018%20V.S.A%20%C2%A7%204637(b)-Avenacy.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Notice%20of%20New%20Drug%20Introduction%20Pursuant%20to%2018%20V.S.A%20%C2%A7%204637(b).pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/OPSYNVI%20approval.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Re_%20Prescription%20Drug%20Manufacturers%20and%20SB%20216%20(Act%20165)_SB%2092%20(Act%20193).pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Takeda-%20EOHILIA-%20Vermont-New-Drug-Notice-20240222.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Tazarotene%20VT%2030%20Day%20Report.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Vermont%20Darunavir%20Report.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Vermont%20Notice%20of%20New%20Drug%20Introduction%20Pursuant%20to%2018%20V.S.A%20%C2%A7%204637(b).pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Vermont%20WAC%20Reporting%20-%20Zinc%20Sulfate%20Injection%202.16.2024.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20-%20New%20Drug%20Notice%20(30-day)%20Coherus.docx.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%202023%20Cover%20Letter%20-%20Disclosure%20and%20Samples%20Report.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%203%20Day%20Posaconazole%20Notice%2003-25-24.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Act%20193%20New%20Drug%20Notice%20Follistim%201.8.24%20JW.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Act%20193%20New%20Drug%20Notice_Due%20launch%20%2B3%20days%20bh.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Act%20193%20New%20Drug%20Report%20pdf.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Act%20193%20New%20Drug%20Report_Est%20Due%20Date_3.20.2024_MR_Draft_BH.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Fresenius%20Kabi%20Posaconazole%2030-day%20Report.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Letter%20to%20Office%20of%20Attorney%20General_New%20Drug%20Report%20Email%20-%20Esmolol.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Letter%20to%20Office%20of%20Attorney%20General_New%20Drug%20Report%20Email%20-%20Nitrofurantoin.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Letter%20to%20Office%20of%20Attorney%20General_New%20Drug%20Report%20Email%20-%20Pemrydi%20RTU.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Letter%20to%20Office%20of%20Attorney%20General_New%20Drug%20Report%20Email%20-%20Ropivacaine%20(1).pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Letter%20to%20Office%20of%20Attorney%20General_New%20Drug%20Report%20Email%20-%20Ropivacaine.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Notice%20(1).pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Notice%20(2).pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Notice%20(3).pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Notice%203%20Day-ROZLYTREK%20ORAL%20Approved.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Notice.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Pricing%20Report%20-%20ALVAIZ%E2%84%A2%20(eltrombopag%20tablets).pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Pricing%20Report%20-%20FINGOLIMOD%20HCL.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Pricing%20Report%20-%20MIFEPRISTONE%20TABLETS.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Pricing%20Report%20-%20RISPERIDONE%20SR%20INJ.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Pricing%20Report%20-%20TERIPARATIDE%20INJ%20PEN.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Report%20-%2030-Day%20Report.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Report%20-%20EOHILIA.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Report%202.28.24.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Report.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Reporting%20-%20Filsuvez.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Reporting%2030%20Day-Rozlyrek%20Oral%20Pellets.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Notice%20of%20New%20Drug%20Introduction%20-%20ALVAIZ%E2%84%A2%20(eltrombopag%20tablets).pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Notice%20of%20New%20Drug%20Introduction%20-%20FINGOLIMOD%20HCL%20CAPS.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Notice%20of%20New%20Drug%20Introduction%20-%20Mifepristone%20Tabs%20.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Pharmaceutical%20Cost%20Transparency%20-%20%20Apotex%20Corp%20-%20Azacitidine%20Inj%20-%2030%20Day%20Reporting%20(1_11).pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Pharmaceutical%20Cost%20Transparency%20-%20Altor%20BioScience%2C%20LLC%20-%20Anktiva%20Launch%20Reporting.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Pharmaceutical%20Cost%20Transparency%20-%20Biocon%20Biologics%20Inc.%20-%20Adalimumab%20Launch%20Reporting.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Pharmaceutical%20Cost%20Transparency%20-%20GC%20Biopharma%20USA%2C%20Inc.%20-%20Alyglo%20Launch%20Reporting.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Product%20Launch%2030%20Days%20Submission.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Report_Tiopronin%20DR.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Signed%20New%20Drug%20Notice%20(1).pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Signed%20New%20Drug%20Notice.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20Solaris-%20Tazarotene%20New%20Product%203-day%20Notice.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT_30-Day-Reporting%20FABHALTA%20HGC%20200MG%2060.pdf.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT_30-Day-Reporting%20Wainua.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT_30-Day-Reporting-Locametz.doc.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT_New%20Prescription%20Drug%20Report%20-AGAMREE.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT_New%20Prescription%20Drug%20Report%20IWILFIN%2001182024.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT_New%20Prescription%20Drug%20Report%20IWILFIN.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT_Product_Notification_3Day%20Wainua.pdf

https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/Zilbrysq%20Vermont%20New%20Drug%20Notice.pdf